All In Biotech

NDA 210064 · Teva Pharms USA

Fosaprepitant Dimeglumine

Fosaprepitant Dimeglumine · Intravenous

Last checked: Nov 20, 2026Latest source record: Sep 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Sep 5, 2019

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

21

7 Phase 3, 0 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Fosaprepitant Dimeglumine" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fosaprepitant Dimeglumine (Fosaprepitant Dimeglumine)

2024 spending

$520K

Beneficiaries

720

2,709 claims

Per beneficiary

$722

$83.66 per unit

View as table
YearSpending
2020$209,749
2021$239,361
2022$282,063
2023$470,810
2024$519,524

Part B: Fosaprepitant Dimeglumine (Fosaprepitant Dimeglumine) · HCPCS J1456

2024 spending

$275K

Beneficiaries

533

1,354 claims

Per beneficiary

$517

2024 ASP limit $1.64 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$97,295
2024$275,385

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.